PoliticsItalySwedenEU

Eating meat makes you resistant to antibiotics

15.03.2012 - Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European Centre for Disease Prevention and Control (ECDC).

High resistance levels were recorded to ampicillin, tetracyclins and sulfonamides in Salmonella isolates from humans (13%-75%), whereas resistance to third-generation cephalosporins and fluoroquinolones remained low (0.2%-7%). In Campylobacter isolates from human cases, resistance to ampicillin, ciprofloxacin, nalidicic acid, and tetracyclins were high (21%-84%), while resistance to erythromycin was recorded at low to moderate levels (0.5%-25%). Most resistances are transmitted by meat consumption from animals that have become resistant to antibiotics, according to the „EU report on antimicrobial resistnce in zoonotic bacteria affecting humans, animals, and foods.“ The highest occurrence to ciproflaxin was noted in Salmonella from turkeys (28%) followed by fowl and broiler meat (24%). High resistance, ranging from 37% to 84% was also observed in Campylobacter isolates from fowl, pigs, and cattle. Methcillin-resistant Staphylococcus aureus (MRSA) in food and animals occurred at levels varying from 0% to 79%, and was most commonly found in turkeys. The surveillance data, which form the base of the report, were submitted in 2010 by 26 EU member states.

http://www.european-biotechnology-news.com/news/news/2012-01/eating-meat-makes-you-resistant-to-antibiotics.html

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Clinical ResearchFrancePortugal

21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.

Immuno-oncologyNetherlandsBelgium

21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.

RegulatorySwitzerlandEU

20.04.2016 The US government is forking out up to US$100m to get Basilea Pharmaceutica’s broad-spectrum antibiotic ceftobiprole on the US market. In the EU, ceftobiprole is already available.

Immuno-oncologyUK

19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.

FinancingSwitzerlandFranceEUGermanyDenmark

15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.

Event ReviewSwitzerlandBelgiumEU

13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.

FinancingGermanyNetherlandsEU

12.04.2016 German-Dutch life science investment specialist Forbion Capital Partners has raised more than €180m for its venture capital fund Forbion Capital Fund III. Once more the money will primarily go to European start-ups.

Event ReviewGermanyEU

08.04.2016 Do you win by being innovative?, was the question asked at this year’s DIA Euromeeting in Hamburg. In a relaxed and cooperative atmosphere, regulators, physicians and patients had ample opportunity to interact with the healthcare industry.

M&AIrelandEU

07.04.2016 Pfizer and Allergan have called off their merger, cancelling plans to relocate the US pharma giant to Ireland to avoid US taxation. The US government has put a spoke in Pfizer’s wheels - an unfair move, Allergan says.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

München

BioVaria 2016

Berlin (GER)

XIV. BIONNALE 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • THERAMETRICS (CH)0.03 CHF50.00%
  • PLETHORA (UK)3.38 GBP12.67%

FLOP

  • OXFORD BIOMEDICA (UK)5.52 GBP-8.76%
  • IXICO (UK)39.00 GBP-4.88%
  • BIONOR PHARMA (N)0.85 NOK-4.49%

TOP

  • AB SCIENCE (F)19.21 EUR70.8%
  • SYNAIRGEN (UK)36.25 GBP48.0%
  • BIOFRONTERA (D)3.14 EUR42.7%

FLOP

  • THERAMETRICS (CH)0.03 CHF-25.0%
  • SERODUS (N)1.70 NOK-22.4%
  • OREXO (S)51.75 SEK-15.5%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)31.40 SEK2036.1%
  • NICOX (F)8.73 EUR361.9%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.00 SEK-88.2%
  • BB BIOTECH (D)47.86 EUR-81.8%
  • BIOTEST (D)17.00 EUR-76.1%

No liability assumed, Date: 29.04.2016